Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2012 2
2013 2
2014 1
2015 1
2016 3
2017 1
2018 3
2019 3
2020 7
2021 7
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE. Bensch F, et al. Among authors: schroder cp. Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26. Nat Med. 2018. PMID: 30478423 Clinical Trial.
Molecular Imaging in Cancer Drug Development.
Waaijer SJH, Kok IC, Eisses B, Schröder CP, Jalving M, Brouwers AH, Lub-de Hooge MN, de Vries EGE. Waaijer SJH, et al. Among authors: schroder cp. J Nucl Med. 2018 May;59(5):726-732. doi: 10.2967/jnumed.116.188045. Epub 2018 Jan 25. J Nucl Med. 2018. PMID: 29371402 Free article. Review.
Molecular imaging as biomarker for treatment response and outcome in breast cancer.
van Geel JJL, de Vries EFJ, van Kruchten M, Hospers GAP, Glaudemans AWJM, Schröder CP. van Geel JJL, et al. Among authors: schroder cp. Ther Adv Med Oncol. 2023 May 18;15:17588359231170738. doi: 10.1177/17588359231170738. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37223262 Free PMC article. Review.
Consideration of breast cancer subtype in targeting the androgen receptor.
Venema CM, Bense RD, Steenbruggen TG, Nienhuis HH, Qiu SQ, van Kruchten M, Brown M, Tamimi RM, Hospers GAP, Schröder CP, Fehrmann RSN, de Vries EGE. Venema CM, et al. Among authors: schroder cp. Pharmacol Ther. 2019 Aug;200:135-147. doi: 10.1016/j.pharmthera.2019.05.005. Epub 2019 May 8. Pharmacol Ther. 2019. PMID: 31077689 Free article. Review.
Application of PET Tracers in Molecular Imaging for Breast Cancer.
Boers J, de Vries EFJ, Glaudemans AWJM, Hospers GAP, Schröder CP. Boers J, et al. Among authors: schroder cp. Curr Oncol Rep. 2020 Jul 6;22(8):85. doi: 10.1007/s11912-020-00940-9. Curr Oncol Rep. 2020. PMID: 32627087 Free PMC article. Review.
Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
van Geel JJL, Boers J, Elias SG, Glaudemans AWJM, de Vries EFJ, Hospers GAP, van Kruchten M, Kuip EJM, Jager A, Menke-van der Houven van Oordt WC, van der Vegt B, de Vries EGE, Schröder CP; IMPACT-Metastatic Breast Consortium. van Geel JJL, et al. Among authors: schroder cp. J Clin Oncol. 2022 Nov 1;40(31):3642-3652. doi: 10.1200/JCO.22.00400. Epub 2022 May 18. J Clin Oncol. 2022. PMID: 35584346
35 results